double negative T-cell therapy (Protheragen)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namedouble negative T-cell therapy (Protheragen)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunomodulatorsT lymphocytes modulators
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesProtheragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesProtheragen Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A